Antibody-drug conjugates: Design and development for therapy and imaging in and beyond cancer, LabEx MAbImprove industrial workshop, July 27-28, 2017, Tours, France.

about

Drug conjugates—an emerging approach to treat breast cancer.DNA damaging agent-based antibody-drug conjugates for cancer therapy

P2860

Q55438401-0C1B5B47-DA7E-4A88-8235-653C9910BDF6 Q57192403-5E60A2AC-2611-45CE-AC80-9A4EB8B2EFDC

P2860

Antibody-drug conjugates: Design and development for therapy and imaging in and beyond cancer, LabEx MAbImprove industrial workshop, July 27-28, 2017, Tours, France.

Item

http://www.wikidata.org/entity/Q49846411

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Antibody-drug conjugates: Desi ...... ly 27-28, 2017, Tours, France.

@en

Antibody-drug conjugates: Desi ...... ly 27-28, 2017, Tours, France.

@nl

type

Item

label

Antibody-drug conjugates: Desi ...... ly 27-28, 2017, Tours, France.

@en

Antibody-drug conjugates: Desi ...... ly 27-28, 2017, Tours, France.

@nl

prefLabel

Antibody-drug conjugates: Desi ...... ly 27-28, 2017, Tours, France.

@en

Antibody-drug conjugates: Desi ...... ly 27-28, 2017, Tours, France.

@nl

P1476

Antibody-drug conjugates: Desi ...... ly 27-28, 2017, Tours, France.

@en

P2093

Claire Kizlik-Masson

http://www.w3.org/2001/XMLSchema#string

Hervé Watier

http://www.w3.org/2001/XMLSchema#string

Marie-Claude Viaud-Massuard

http://www.w3.org/2001/XMLSchema#string

Nicolas Joubert

http://www.w3.org/2001/XMLSchema#string

P2860

Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes"

Comparative clinical pharmacokinetics of antibody-drug conjugates in first-in-human Phase 1 studies

Structure-based design of beta 1,4-galactosyltransferase I (beta 4Gal-T1) with equally efficient N-acetylgalactosaminyltransferase activity: point mutation broadens beta 4Gal-T1 donor specificity

Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency

TP53 loss creates therapeutic vulnerability in colorectal cancer.

Current and future issues in the manufacturing and development of monoclonal antibodies.

EndoS2 is a unique and conserved enzyme of serotype M49 group A Streptococcus that hydrolyses N-linked glycans on IgG and α1-acid glycoprotein.

Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize.

Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.

P304

210-221

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/19420862.2017.1412130

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

André Pèlegrin

Camille Martin

P577

2018-01-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29239690

http://www.w3.org/2001/XMLSchema#string

P932

5825198

http://www.w3.org/2001/XMLSchema#string

Antibody-drug conjugates: Design and development for therapy and imaging in and beyond cancer, LabEx MAbImprove industrial workshop, July 27-28, 2017, Tours, France.

about

P2860

P2860

Antibody-drug conjugates: Design and development for therapy and imaging in and beyond cancer, LabEx MAbImprove industrial workshop, July 27-28, 2017, Tours, France.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932